AbbVie Inc (NYSE:ABBV) Shares Sold by Moneta Group Investment Advisors LLC
Moneta Group Investment Advisors LLC lowered its stake in shares of AbbVie Inc (NYSE:ABBV) by 36.5% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,695 shares of the company’s stock after selling 3,852 shares during the quarter. Moneta Group Investment Advisors LLC’s holdings in AbbVie were worth $729,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently bought and sold shares of the company. Strategic Global Advisors LLC raised its position in AbbVie by 0.7% in the second quarter. Strategic Global Advisors LLC now owns 31,559 shares of the company’s stock valued at $2,295,000 after purchasing an additional 215 shares during the period. MML Investors Services LLC raised its holdings in shares of AbbVie by 11.1% in the 2nd quarter. MML Investors Services LLC now owns 229,235 shares of the company’s stock valued at $16,670,000 after buying an additional 22,908 shares during the period. Toronto Dominion Bank boosted its holdings in AbbVie by 13.5% during the 2nd quarter. Toronto Dominion Bank now owns 1,281,032 shares of the company’s stock valued at $93,134,000 after acquiring an additional 152,462 shares during the period. Natixis boosted its holdings in AbbVie by 182.4% during the 2nd quarter. Natixis now owns 1,767,620 shares of the company’s stock valued at $128,541,000 after acquiring an additional 1,141,797 shares during the period. Finally, Ossiam purchased a new stake in AbbVie during the second quarter worth about $78,000. Hedge funds and other institutional investors own 68.21% of the company’s stock.
ABBV stock traded up $1.37 during trading on Wednesday, hitting $69.55. The company had a trading volume of 576,889 shares, compared to its average volume of 7,585,533. The firm has a market cap of $98.61 billion, a PE ratio of 8.78, a price-to-earnings-growth ratio of 1.58 and a beta of 0.95. AbbVie Inc has a 1-year low of $62.66 and a 1-year high of $96.60. The firm has a 50-day moving average price of $66.10 and a 200-day moving average price of $74.87.
The company also recently disclosed a — dividend, which will be paid on Friday, November 15th. Shareholders of record on Tuesday, October 15th will be paid a $1.07 dividend. The ex-dividend date is Friday, October 11th. This represents a yield of 6.4%. AbbVie’s dividend payout ratio is currently 54.11%.
In other AbbVie news, Director Roxanne S. Austin acquired 11,500 shares of the business’s stock in a transaction on Wednesday, June 26th. The stock was purchased at an average price of $67.50 per share, for a total transaction of $776,250.00. Following the completion of the transaction, the director now owns 52,114 shares of the company’s stock, valued at approximately $3,517,695. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, EVP William J. Chase bought 30,400 shares of AbbVie stock in a transaction on Wednesday, June 26th. The stock was acquired at an average cost of $67.30 per share, with a total value of $2,045,920.00. Following the acquisition, the executive vice president now owns 169,552 shares of the company’s stock, valued at approximately $11,410,849.60. The disclosure for this purchase can be found here. Insiders acquired a total of 159,977 shares of company stock worth $10,626,621 over the last three months. 0.08% of the stock is currently owned by corporate insiders.
Several equities research analysts recently weighed in on the stock. TheStreet downgraded shares of AbbVie from a “b-” rating to a “c” rating in a research note on Monday, August 26th. ValuEngine downgraded AbbVie from a “sell” rating to a “strong sell” rating in a report on Wednesday, June 26th. Piper Jaffray Companies increased their price target on AbbVie from $80.00 to $81.00 and gave the company an “overweight” rating in a research report on Wednesday, September 4th. Wolfe Research raised AbbVie from an “underperform” rating to a “peer perform” rating in a research report on Thursday, June 27th. Finally, Leerink Swann upgraded shares of AbbVie to a “buy” rating in a research note on Tuesday, July 2nd. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and five have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $92.12.
AbbVie Inc discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.
Read More: Why do analysts give a neutral rating?
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc (NYSE:ABBV).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.